Real-World Data Reveals Rise in mHSPC Treatment Intensification скачать в хорошем качестве

Real-World Data Reveals Rise in mHSPC Treatment Intensification

In a three-part series, Umang Swami, MD, University of Utah Health, and Jordan Ciuro, MD, Emory Winship Cancer Institute, discuss findings from a large, real-world analysis using the Flatiron Health database, showing that while fewer than 40% of patients with mHSPC received intensified therapy in 2020, recent data from 2023 onward indicate a substantial shift, with approximately 77% now receiving combination treatments such as ADT with AR pathway inhibitors, docetaxel, or both. The discussion is based around Dr. Swami's 2025 ASCO GU Cancers Symposium research on recent treatment patterns in US-based real-world patients with mHSPC.